Specifications
| Size | 50μL/100μL |
| Target | p16 |
| Reactivity | Human |
| Applications | IHC, WB, IF, ELISA |
| MW(Calculated) | 16kD |
| MW(Observed) | 16kD |
| Host Species | Mouse |
| Isotype | IgG2b,Kappa |
| Conjugate/Modification | Unmodified |
| Recommended Dilution Ratio | IHC 1:200-1000; WB 1:500-2000; IF 1:100-500; ELISA 1:1000-5000 / Note: For IHC, we suggest antigen retrieval with TE buffer pH 9.0 (Cat#WT1004) |
| Formulation | PBS, 50% glycerol, 0.05% Proclin 300, 0.05%BSA |
| Purification | Recombinant Antibody expressed in animal component-free (ACF) media, purified via Protein G affinity chromatography. |
| Storage | -15°C to -25°C/1 year(Do not lower than -25°C) |
| Concentration | |
| Clonality | Monoclonal |
| Clone Number | RMMR2301 |
| Immunogen | Synthesized peptide derived from human p16 INK AA range: 100-156 |
| Specificity | This antibody detects endogenous levels of p16 INK protein. |
| Gene Name | CDKN2A CDKN2 MTS1 |
| Protein Name | Cyclin-dependent kinase inhibitor 2A isoforms 1/2/3 |
| Other Name | CDKN2A; / CDKN2; / MTS1; / Cyclin-dependent kinase inhibitor 2A; / isoforms 1/2/3; / Cyclin-dependent kinase 4 inhibitor A; / CDK4I; / Multiple tumor suppressor 1; / MTS-1; / p16-INK4a; / p16-INK4; / p16INK4A; / p16 |
| Species | Human |
| Gene ID | 1029 |
| Uniprot | P42771 |
| Species.1 | |
| Gene ID.1 | |
| Uniprot.1 | |
| Species.2 | |
| Gene ID.2 | |
| Uniprot.2 | |
| Cellular Localization | Nuclear |
| Tissue Expression | Widely expressed but not detected in brain or skeletal muscle. Isoform 3 is pancreas-specific. |
| Signaling_pathway | Cellular Processes >> Cell growth and death >> Cell cycle;Cellular Processes >> Cell growth and death >> p53 signaling pathway;Cellular Processes >> Cell growth and death >> Cellular senescence;Human Diseases >> Cancer: overview >> Pathways in cancer;Human Diseases >> Cancer: overview >> MicroRNAs in cancer;Human Diseases >> Cancer: specific types >> Pancreatic cancer;Human Diseases >> Cancer: specific types >> Hepatocellular carcinoma;Human Diseases >> Cancer: specific types >> Glioma;Human Diseases >> Cancer: specific types >> Chronic myeloid leukemia;Human Diseases >> Cancer: specific types >> Melanoma;Human Diseases >> Cancer: specific types >> Bladder cancer;Human Diseases >> Cancer: specific types >> Non-small cell lung cancer |
| Research Areas | |
| Function | Alternative products:Isoform 1 and isoform 4 arise due to the use of two alternative first exons joined to a common exon 2 at the same acceptor site but in different reading frames, resulting in two completely different isoforms,Disease:Defects in CDKN2A are a cause of Li-Fraumeni syndrome (LFS) [MIM:151623]. LFS is a highly penetrant familial cancer phenotype usually associated with inherited mutations in TP53.,Disease:Defects in CDKN2A are involved in tumor formation in a wide range of tissues.,Disease:Defects in CDKN2A are the cause of cutaneous malignant melanoma 2 (CMM2) [MIM:155601]. Inheritance is autosomal dominant. Malignant melanoma is a malignant neoplasm of melanocytes, arising de novo or from a preexisting benign nevus, which occurs most often in the skin but also may involve other sites.,Disease:Defects in CDKN2A are the cause of familial atypical multiple mole melanoma-pancreatic carcinoma syndrome (FAMMMPC) [MIM:606719].,Disease:Defects in CDKN2A are the cause of melanoma-astrocytoma syndrome [MIM:155755]. The melanoma-astrocytoma syndrome is characterized by a dual predisposition to melanoma and neural system tumors, commonly astrocytoma.,Function:Acts as a negative regulator of the proliferation of normal cells by interacting strongly with CDK4 and CDK6. This inhibits their ability to interact with cyclins D and to phosphorylate the retinoblastoma protein.,Function:Capable of inducing cell cycle arrest in G1 and G2 phases. Acts as a tumor suppressor. Binds to MDM2 and blocks its nucleocytoplasmic shuttling by sequestering it in the nucleolus. This inhibits the oncogenic action of MDM2 by blocking MDM2-induced degradation of p53 and enhancing p53-dependent transactivation and apoptosis. Also induces G2 arrest and apoptosis in a p53-independent manner by preventing the activation of cyclin B1/CDC2 complexes. Binds to BCL6 and down-regulates BCL6-induced transcriptional repression. Binds to E2F1 and MYC and blocks their transcriptional activator activity but has no effect on MYC transcriptional repression. Binds to TOP1/TOPOI and stimulates its activity. This complex binds to rRNA gene promoters and may play a role in rRNA transcription and/or maturation. Interacts with NPM1/B23 and promotes its polyubiquitination and degradation, thus inhibiting rRNA processing. Interacts with UBE2I/UBC9 and enhances sumoylation of a number of its binding partners including MDM2 and E2F1. Binds to HUWE1 and represses its ubiquitin ligase activity. May play a role in controlling cell proliferation and apoptosis during mammary gland development.,online information:Database of CDKN2A germline and somatic variants,online information:P16INK4a entry,polymorphism:Genetic variations in CDKN2A may underlie susceptibility to uveal melanoma [MIM:155720]. Uveal melanoma is the most common type of ocular malignant tumor, consisting of overgrowth of uveal melanocytes and often preceded by a uveal nevus.,similarity:Belongs to the CDKN2 cyclin-dependent kinase inhibitor family.,similarity:Contains 4 ANK repeats.,subunit:Does not interact with cyclins, CDC2, CDK2, CDK4, CDK5 or CDK6. Binds to BCL6, E2F1, HUWE1, MDM2, MYC, NPM1/B23, TOP1/TOPOI and UBE2I/UBC9. Interacts with TBRG1. Interacts with CDKN2AIP and E4F1.,subunit:Heterodimer with CDK4 or CDK6. Isoform 3 does not bind to CDK4.,tissue specificity:Widely expressed but not detected in brain or skeletal muscle. Isoform 3 is pancreas-specific., |
